# HOEFORD
## Results You Can Trust

# SAFEGUARDING SAMPLE INTEGRITY AND QUALITY IN LIFE SCIENCES:

Importance, Regulatory Compliance, Financial and Scientific Implications

## AT A GLANCE

### CHALLENGES

- GMP regulations
- Regulatory consequences
- Regulatory warnings process
- Failure to adhere to GMP

### IMPLICATIONS

- Direct and indirect financial risks
- Scientific implications
- Costs to the scientific ecosystem

## OBJECTIVE

The preservation of sample integrity and quality in life sciences research is a foundational principle essential for achieving accurate, reproducible, and reliable results. The adherence to stringent standards such as Good Manufacturing Practices (GMP) and regulatory guidance, is paramount to ensure that samples, whether biological, chemical, or environmental, maintain their integrity throughout handling, storage, and analysis.

Here we provide an in-depth evaluation of the consequences of sample integrity breaches. These include not only regulatory warnings, but may also lead to significant financial and scientific costs.

## STANDARDS AND REGULATIONS

Good Manufacturing Practices (GMP) represent a set of quality assurance principles and operational protocols that govern the manufacturing, testing, and distribution of pharmaceuticals, biologics, medical devices, and other healthcare products. Established to ensure the safety, efficacy, and quality of products intended for human use, GMP standards emphasise the importance of quality control, documentation, validation, and risk management throughout the product lifecycle.

In the context of sample integrity and quality, adherence to GMP principles is indispensable for minimising risks associated with contamination, adulteration, and variability in sample composition,

www.Hoeford.com

## ABOUT THE AUTHOR

Hoeford Research Ltd is a privately-owned MHRA GMP-compliant and FDA-registered laboratory. Our customers utilise our contract testing services for the essential work of ensuring their products meet regulatory safety requirements.

We offer pharmaceutical companies a streamlined, cost effective and high-quality path through preclinical drug development stages.

# HOEFORD
*Results You Can Trust*

Regulatory guidance documents outline best practices, validation protocols, and quality control measures relevant to various aspects of sample management, including sampling procedures, storage conditions, analytical methods, and data integrity.

This upholds the reliability and reproducibility of experimental data and regulatory submissions. Regulatory agencies also play a pivotal role in setting and enforcing standards of quality, safety, and compliance within the life sciences industry. Through the issuance of guidance documents, regulations, and inspections, regulatory authorities provide clear expectations and requirements for ensuring sample integrity and quality in research, development, manufacturing, and distribution activities.

Yet despite the existence of these frameworks and standards, instances of non-compliance and breaches in sample integrity continue to pose significant challenges and risks to the life sciences sector.

## REGULATORY WARNINGS

In any given year in the United States, most of the warning letters issued by the Federal Drug Administration (FDA) will cite issues with data integrity. The FDA regularly issues warnings, citations, and enforcement actions against companies found to be in violation of GMP requirements and regulatory standards related to sample integrity. These warnings are highly visible, public notices highlighting deficiencies, deviations, and lapses in quality control measures.

All of which may compromise the safety, efficacy, and reliability of products and research outcomes. These FDA warning letters often cite concerns regarding inadequate documentation of sample handling procedures, insufficient controls for preventing cross-contamination, or failure to validate analytical methods used for testing samples. Such deficiencies not only undermine the credibility and reliability of data generated but also pose potential risks to patient safety, public health, and regulatory compliance.

Companies receiving FDA warnings are typically required to implement corrective actions, remediation plans, and quality improvement initiatives to address identified deficiencies and prevent recurrence of non-compliance.

## SIGNIFICANT FINANCIAL IMPLICATIONS

Sample integrity directly influences research reproducibility from early ideation through scale up and manufacturing. The integrity of samples, materials and related data is intrinsically important when striving to replicate or reproduce research results.

The financial costs associated with sample integrity breaches and regulatory non-compliance are substantial, and include direct expenses related to remediation efforts, regulatory fines and legal fees, as well as indirect costs stemming from reputational damage, market loss, and business disruptions.

The most recent in-depth study on the economic costs associated with low reproducibility rates dates from 2015 and estimated that in the United States alone US$28 billion per year was being spent on research that is not reproducible. That equals over US$37 billion in today's money. The study also showed that over half of all preclinical research was irreproducible and that while flawed preclinical studies represent a huge issue in both cost and time for life science organisations, they also create false hope for patients waiting for lifesaving cures.

# HOEFORD
*Results You Can Trust*

## The impact of sample degradation extends beyond individual companies to the broader life sciences ecosystem, encompassing contract research organisations, academic institutions, and regulatory agencies involved in research, development, and oversight activities

## THE SCIENTIFIC COST

Irreproducibility as a result of sample integrity breaches points to systemic and costly inefficiencies in the way preclinical studies are designed, conducted, and reported, and because replication and cumulative knowledge production are cornerstones of the scientific process, this is scientifically troubling.

Sample integrity fluctuations can have detrimental effects that extend beyond individual companies, penetrating the broader life sciences ecosystem which encompasses contract research organisations (CROs), academic institutions, regulatory agencies and other businesses involved in the various phases of research, development, and oversight activities.

The loss of trust and credibility resulting from sample integrity lapses can erode public confidence in the safety and efficacy of medical products, undermine collaborative research efforts, and impede innovation in the discovery and development of new therapies and technologies.

Mitigating the risks and consequences associated with sample integrity breaches requires collaboration and knowledge-sharing among industry stakeholders, regulatory agencies, and professional associations.

In a bid to proactively uphold standards of quality, compliance, and accountability throughout the sample lifecycle, this entails establishing robust quality management systems, implementing comprehensive training programs, fostering a culture of quality and continuous improvement across organisational functions while promoting transparency, harmonising standards, and advancing best practices in sample management and quality assurance.

In conclusion, the necessity for sample integrity and quality in life sciences transcends regulatory compliance and encompasses broader imperatives related to patient safety, scientific integrity, and industry sustainability.

By adhering to Good Manufacturing Practices (GMP) and regulatory guidance, stakeholders can uphold standards of quality, consistency, and compliance throughout the sample lifecycle, thereby mitigating risks, fostering innovation, and enhancing public trust in the safety and efficacy of medical products.

Through proactive risk management, continuous improvement, and collaborative engagement, the life sciences sector can effectively address challenges related to sample integrity breaches and uphold its commitment to delivering safe, effective, and reliable products for the betterment of global health and well-being.